. Author manuscript; available in PMC: 2016 Sep 1.

Published in final edited form as: Parkinsonism Relat Disord. 2015 Jun 21;21(9):1072–1075. doi: 10.1016/j.parkreldis.2015.06.017

Table 1.

Demographic and clinical characteristics of FMD patients and healthy controls.

	FMD	HC	p-value^a
Number of subjects	33	33
Age	43.4 ± 11.6	41 ± 10.1	0.41
Sex, female/male	25/8	24/9	0.78
Females using oral contraception	4 (16%)	1 (4%)	0.18
Cigarette smokers	3 (9%)	2 (6%)	0.65
History of mood disorder	15 (45%)	4 (12%)	0.002
History of anxiety disorder	21 (64%)	9 (27%)	0.002
History of post-traumatic stress disorder	8 (24%)	4 (12%)	0.21
Taking CNS-acting medication^b	19 (58%)	0	< 0.001
Disease duration, years (range)	4.69 ± 4.97 (0.4 – 19)	-	-

by 2-tailed student’s t-test;

CNS-acting medications included clonazepam (n=8), lorazepam (n=2), alprazolam (n=1), duloxetine (n=2), gabapentin (n=6), trihexyphenidyl (n=2), carbidopa-levodopa (n=1), ropinirole (n=1), baclofen (n=1), citalopram (n=1), sertraline (n=3), acetazolamide (n=2), desvenlafaxine (n=1), and adderall (n=1).